ProShare Advisors LLC Has $2.06 Million Position in Charles River Laboratories International, Inc. $CRL

ProShare Advisors LLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 50.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,153 shares of the medical research company’s stock after buying an additional 4,386 shares during the quarter. ProShare Advisors LLC’s holdings in Charles River Laboratories International were worth $2,058,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of CRL. Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International in the second quarter valued at about $29,000. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $31,000. Geneos Wealth Management Inc. increased its holdings in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. Allworth Financial LP raised its position in shares of Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after buying an additional 190 shares in the last quarter. Finally, SJS Investment Consulting Inc. bought a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $48,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 1.5%

CRL stock opened at $161.15 on Friday. The firm has a 50-day moving average price of $203.27 and a 200-day moving average price of $179.68. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $7.93 billion, a P/E ratio of -103.30, a price-to-earnings-growth ratio of 4.84 and a beta of 1.63.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Citigroup raised their price target on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, December 15th. Barclays raised their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a report on Monday, December 1st. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $209.46.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.